FOXP3 and neoplasm: Small molecule AKT activator, SC79, impaired the growth of poor immunotherapy responder murine tumours, B16 and EMT-6 suppressing CD4+Foxp3+Treg TILs through the conversion of Tregs to IFNγ+CD4+Th1-like T cells [52].